Elagolix is a Gonadotropin-Releasing Hormone (GnRH) Antagonist.

Elbasvir (MK-8742) is a small-molecule inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) being developed as a component of treatment regimens for chronic HCV infection.

Eldecalcitol (ED-71; 2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitamin D3) is an analog of 1,25-dihydroxyvitamin D3 that improves bone mineral density. Eldecalcitol (ED-71; 2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitamin D3) is more efficaci

Eleclazine(GS-6615) is a selective late sodium current inhibitor.

Elenbecestat (E2609) is a novel potent, oral BACE1 inhibitor for treatment of Alzheimer's disease..

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that illicits pro-apoptosis events among tumor cells..

Eletriptan HBr is an orally active, selective 5-HT1B/1D receptor agonist.

Eliglustat is a specific and potent inhibitor of glucosylceramide synthase.

Eliglustat is a specific and potent inhibitor of glucosylceramide synthase.

Eliprodil is a non-competitive NMDA receptor antagonist that acts at the polyamine modulatory site.

Ellipticine hydrochloride is a potent antineoplastic agent; inhibits DNA topoisomerase II activities.

Ellipticine is a DNA intercalating agent and a DNA topoisomerase II inhibitor.

ELN-441958 is a potent, neutral antagonist of B1 receptor, inhibits the binding of the B1 agonist ligand [3H]DAKD to IMR-90 cells with Ki of 0.26 nM. ELN-441958 is highly selective for B1 over B2 receptors, and >500/ 2000-fold selective for the B1 over μ/δ-opioid receptor.IC50 value: 0.26 nM (Ki)Target: B1 Receptorin vitro: ELN-441958 is a novel small molecule bradykinin B1 receptor antagonist, based on the inhibition of agonist-induced increases in intracellular calcium in native and recombinant cells. ELN-441958 does not inhibit the activation of the human bradykinin B2 receptor at concentrations up to 10 μM, showing that it is highly selective for B1 over B2 receptors. ELN-441958 also displays good selectivity for B1 over other receptors examined in a broad screening panel. It is >500-fold and >2000-fold selective for the B1 receptor over the human μ- and δ-opioid receptor, the most potent off-target activity identified. In IMR-90 cells expressing the native human B1 receptor, ELN-441958 produced a concentration-dependent antagonism of the DAKD-induced calcium mobilization with a KB of 0.12 nM. [1]in vivo: ELN-441958 is essentially completely absorbed and produces high plasma levels after oral administration in rhesus monkeys.ELN-441958 has a moderate clearance and volume of distribution in both species following i.v. administration, consistent with the high metabolic stability in rat, rhesus, and human microsomes. ELN-441958 has high oral exposure and moderate plasma half-lives in rats and rhesus monkeys. The oral availability of ELN441958 in rats was 57%. ELN-441958 dose-dependently reduced carrageenan-induced thermal hyperalgesia in a rhesus monkey tail-withdrawal model, with an ED50 3 mg/kg s.c. [1]

ELN484228 is a blocker of α-synuclein which is a key protein in Parkinson’s disease.

ELQ300 is a novel inhibitor of the mitochondrial cytochrome bc1 complex (complex III in the electron transport chain).

Eltrombopag (SB-497115-GR)

Eltrombopag olamine is a new, orally active thrombopoietin-receptor (c-mpl) agonist that stimulates thrombopoiesis.

Eluxadoline Dihydrochloride is an orally active mixed μ opioid receptor (μOR) agonist δ opioid receptor (δOR) antagonist.

Eluxadoline is an orally active mixed μ opioid receptor (μOR) agonist δ opioid receptor (δOR) antagonist.

Elvitegravir (EVG) is a drug used for the treatment of HIV infection. It acts as an integrase inhibitor.

EMA400 is a potent and highly selective AT2R antagonist.

EMA401(Olodanrigan) is a highly selective AT2R antagonist, inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.